Novo Nordisk A/S $NVO Shares Purchased by Freedom Investment Management Inc.

Freedom Investment Management Inc. boosted its stake in Novo Nordisk A/S (NYSE:NVO) by 8.4% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 22,557 shares of the company’s stock after acquiring an additional 1,753 shares during the period. Freedom Investment Management Inc.’s holdings in Novo Nordisk A/S were worth $1,557,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in NVO. Revolve Wealth Partners LLC raised its stake in shares of Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after buying an additional 200 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Novo Nordisk A/S by 9.6% during the 1st quarter. GAMMA Investing LLC now owns 9,466 shares of the company’s stock worth $657,000 after buying an additional 827 shares in the last quarter. Spire Wealth Management raised its stake in shares of Novo Nordisk A/S by 8.2% during the 1st quarter. Spire Wealth Management now owns 12,862 shares of the company’s stock worth $893,000 after buying an additional 978 shares in the last quarter. Golden State Wealth Management LLC raised its stake in shares of Novo Nordisk A/S by 127.1% during the 1st quarter. Golden State Wealth Management LLC now owns 4,128 shares of the company’s stock worth $287,000 after buying an additional 2,310 shares in the last quarter. Finally, HBK Sorce Advisory LLC raised its stake in shares of Novo Nordisk A/S by 13.2% during the 1st quarter. HBK Sorce Advisory LLC now owns 11,154 shares of the company’s stock worth $775,000 after buying an additional 1,302 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

NVO has been the subject of a number of analyst reports. Wall Street Zen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. UBS Group cut Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a report on Tuesday, August 5th. Rothschild & Co Redburn upgraded Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, September 16th. Finally, BNP Paribas Exane upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 price target on the stock in a report on Wednesday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $76.00.

Novo Nordisk A/S Trading Down 0.3%

NYSE:NVO opened at $53.24 on Friday. The business’s 50-day moving average is $56.55 and its two-hundred day moving average is $62.45. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. Novo Nordisk A/S has a 12 month low of $45.05 and a 12 month high of $115.26. The firm has a market capitalization of $237.70 billion, a PE ratio of 14.63, a price-to-earnings-growth ratio of 2.43 and a beta of 0.68.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The company had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. Research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were given a dividend of $0.4119 per share. This represents a dividend yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S’s payout ratio is presently 22.53%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.